Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509731 | 0.94 | MMP13 (0.47) | KCNH2HRH3KMT2APKMALDH1A1 | |
| SCHEMBL7558249 | 0.93 | MMP1 (0.47) | KCNH2HRH3KMT2APKMALDH1A1 | |
| SCHEMBL7505933 | 0.93 | LTA4H (0.47) | KCNH2HRH3KMT2APKMALDH1A1 | |
| SCHEMBL7553439 | 0.91 | MMP1 (0.49) | KCNH2HRH3KMT2APKMALDH1A1 | |
| SCHEMBL7504704 | 0.90 | HRH3 (0.56) | KCNH2HRH3ALDH1A1TSHRS1PR5 | |
| SCHEMBL7510431 | 0.89 | KCNH2 (0.51) | KCNH2HRH3KMT2APKMALDH1A1 | |
| SCHEMBL7510825 | 0.86 | ALDH1A1 (0.52) | KCNH2KMT2APKMALDH1A1KDM4E | |
| SCHEMBL7510687 | 0.85 | MEN1 (0.59) | KCNH2HRH3KMT2AALDH1A1TSHR | |
| SCHEMBL7510863 | 0.84 | POLB (0.54) | KMT2APKMS1PR5MEN1RAB9A | |
| SCHEMBL7510118 | 0.84 | KCNH2 (0.50) | KCNH2HRH3KMT2APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | KCNH2 3171/4885HRH3 1187/4885KMT2A 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.